Tidewave turns a patient’s tumor biopsy into an active input for personalized treatment and ongoing biological insight.
Today, a tumor biopsy is primarily used to diagnose and characterize cancer.
Tidewave is developing a different model: use that same tumor material as an active input for treatment, biological profiling, and longitudinal monitoring.
Every solid tumor contains a complex and changing landscape of antigens. Approaches built around a limited set of selected targets may leave important tumor biology behind.
By using material from the patient's own tumor, the goal is to expose the immune system to a broader picture of that individual cancer.
See more of the tumor.
Bring more immune cells into the fight.
Build toward a response that may last.
Tidewave Bio Cell-1 (TBC-1) is our universal, scalable, off-the-shelf immunotherapy platform personalized in real time, and designed to overcome the toughest challenges of solid tumors, TBC-1 is designed to break through where other have failed.
Tumor material is obtained through the clinical biopsy workflow.
Fresh tissue is processed into a cell-free tumor lysate containing a broad tumor-antigen repertoire.
Universal cryopreserved TBC-1 cells are combined with the patient-specific lysate at or near the treatment site.
The personalized product is designed to prime an immune response against multiple signals from that patient’s cancer.
Patient tumor lysate provides TBC-1 with a broad repertoire of patient-specific tumor antigens rather than a preselected antigen list.
The CXCL9/10-enhanced APC foundation is designed to support T-cell recruitment and intratumoral infiltration.
Published preclinical models showed enhanced activity with anti-PD-1 and durable tumor-specific protection on rechallenge, supporting the rationale for checkpoint combination and immune memory.
Tidewave is designed to connect the original tumor biopsy with what happens after treatment. By bringing together tumor tissue, blood, immune biology, and clinical outcomes over time, the platform can build a richer picture of how cancer responds and changes.
Tidewave is designed to connect steps that are usually separated: preparing tumor material, personalizing treatment, and learning from what happens next.
Preclinical research supports the biological foundation behind TBC-1.
Tidewave completed an FDA INTERACT meeting in August 2025.
Human R&D material has been generated and preliminary biopsy-processing work is underway.
François is a veteran executive with 30 years of experience in advanced cell and gene therapy product development across multiple therapeutic areas. His background includes leadership roles in both startups and major healthcare organizations. He previously served as President of Renovaro Biosciences, CEO of Rediens, and Global Head of Product Development at Lineage Cell Therapeutics, with prior experience at Johnson & Johnson, Medtronic, and Genzyme.
Michael is a physician-scientist with over 25 years of experience in internal medicine, developmental biology, and drug development. He has held senior leadership roles in both biotech startups and major pharma, including Centocor, Johnson & Johnson, and Incyte. He co-founded the Proof-of-Concept Team at J&J and led Global Medical Affairs at Incyte.
Ariel Rodriguez, PhD, is Head of Translational Science at Tidewave Bio, leading translational R&D for the company’s advanced therapy platform. He has extensive experience across molecular biology, preclinical development, gene-modified cellular therapies, and regulatory quality assessment, with prior roles in the U.S. and Europe spanning translational science, biologics evaluation, and advanced therapy development. Dr. Rodriguez has authored more than 25 peer-reviewed publications and is an inventor on several patent applications.
